Congenital ichthyosis: An overview of current and emerging therapies

Acta Dermato-Venereologica

Volumn 88, Issue 1, 2008, Pages 4-14

  Vahlquist, Anders ^a,b   Gånemo, Agneta ^a   Virtanen, Marie ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Collodion baby; Gene therapy; Genodermatosis; Ichthyosis; Keratolytic agents; Retinoids

Indexed keywords

2 HYDROXYACID; ACETYLCYSTEINE; ADAPALENE; ANTIINFECTIVE AGENT; CALCIPOTRIOL; ETRETIN; ETRETINATE; GLYCEROL; GLYCOLIC ACID; ISOTRETINOIN; LACTIC ACID; LIAROZOLE; PETROLATUM; PIMECROLIMUS; PROPYLENE GLYCOL; RETINOIC ACID; RETINOID; SALICYLIC ACID; TAZAROTENE; UREA;

BLEPHARITIS; BLISTER; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; CONJUNCTIVITIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ECTROPION; GENE TRANSFER; GENOTYPE; HUMAN; ICHTHYOSIS VULGARIS; LAMELLAR ICHTHYOSIS; MORBIDITY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SKIN FRAGILITY; TERATOGENICITY; TREATMENT PLANNING;

ANTI-INFECTIVE AGENTS; DERMATOLOGIC AGENTS; EMOLLIENTS; GENE THERAPY; HUMANS; ICHTHYOSIS; INFANT, NEWBORN; KERATOLYTIC AGENTS; RETINOIDS; SKIN;

EID: 38949159705     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0415     Document Type: Review

References (70)

1. Bousema M, van Diggelen O, van Joost T, Stolz E, Naafs F. Ichthyosis: reliability of clinical signs in the differentiation between autosomal dominant and sex-linked forms. Int J Dermatol 1989; 28: 240-242.
2. Fleckman P, Brumbaigh S. Absence of the granular layer and keratohyaline define a morphologically distinct subset of individuals with ichthyosis vulgaris. Exp Dermatol 2002; 11: 327-336.
3. Öhman H, Vahlquist A. The pH gradient over the stratum corneum differs in x-linked recessive and autosomal dominant ichthyosis: a clue to the molecular origin of the acid skin mantle? J Invest Dermatol 1998; 111: 674-677.
4. Elias P, Crumrine D, Rassner U, Hachem J-P, Menon GK, Man W, et al. Basis for abnormal desquamation and permeability barrier dysfunction in RXLI. J Invest Dermatol 2004; 122: 314-319.
5. Sato J, Denda M, Nakanishi J, Nomura J, Koyama J. Cholesterol sulfate inhibits proteases that are involved in desquamation of stratum corneum. J Invest Dermatol 1998; 111: 189-193.
6. Smith FJ, Inane AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, et al. Loss-of-function mutations in the gene endcoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006: 38: 337-342.
7. Scott I, Harding C, Barrett J. Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta 1982; 719: 110-117.
8. DiGiovanna JJ, Robinson-Bostom L. Ichthyosis. Etiology, diagnosis and management. Am J Clin Dermatol 2003; 4: 81-95.
9. Lavrijsen A. Oestmann E, Hermans J, Bodde H, Vermeer B, Ponec M. Barrier function parameters in various keratinzation disorders: transepidermal water loss and vascular response to hexyl nicotinate. Br J Dermatol 1993; 129: 547-554.
10. Nomura K, Nakano H, Umeki K, Harada K, Kon A, Tamal D, et al. A study of the steroid sulfatase gene in families with x-linked ichthtyosis using polymerase chain reaction. Acta Derm Venereol 1995; 75: 340-342.
11. Gånemo A, Pigg M, Virtanen M, Kukk T, Raudsepp H, Rossman-Ringdahl I, et al. Autosomal recessive congenital ichthyosis in Sweden and Estonia: clinical, ultrastructural and genetic findings in 83 patients. Acta Derm Venereol 2003; 83: 24-30.
12. Oji V, Traupe H. Ichthyosis: differential diagnosis and molecular genetics. Eur J Dermatol 2006; 16: 349-359.
13. Vahlquist A, Gånemo A, Pigg M, Virtanen M, Westermark P. The clinical spectrum of congenital ichthyosis in Sweden: a review of 127 cases. Acta Derm Venereol 2003; Suppl. 213: 34-47.
14. Huber M, Rettle I, Berbasconi K, Frenk E, Lavrijsen S, Ponec M, et al. Mutations of keratinocyte transglutaminase in lamellar ichthyosis. Science 1995; 267: 525-528.
15. Ishida-Yamamoto A, Iizuka H. Structural organization of cornified cell envelopes and alterations in inherited skin disorders. Exp Dermatol 1998; 7: 1-10.
16. Lefèvre C, Bouadjar B, Karaduman A, Jobard F, Saker S, Ozguz M, et al. Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet. 2004; 13: 2473-2482.
17. Dahlqvist J, Klar J, Hausser I, Anton-Lamprecht I, Hellström-Pigg M, Gedde-Dahl, Jr, et al. Congenital ichthyosis: mutations in ichthyin associated with specific structural abnormalities in the granular layer of epidermis. J Med Genet 2007; 44: 615-620.
18. Jobard F, Lefévre C, Karaduman A, Blanchet-Bardon C, Emre S, Weissenbach J, et al. Lipozygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet 2002; 11: 107-113.
19. Lefévre C, Jobard F, Caus F, Bouadjar B, Karaduman A, Heilig R, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 2001; 69: 1002-1012.
20. Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest 2005; 115: 1777-1784.
21. Kelsell DP, Norgett EE, Unsworth, The MT, Cullup T, Mein CA, et al. Mutations in ABCA12 underlie the severe congential skin disease Harlequin ichtyhyosis. Am J Hum Genet 2005; 76: 794-803.
22. Smith FJD. The molecular genetics of keratin disorders. Am J Clin Dermatol 2003; 4: 347-364.
23. Schmuth M, Yosipovitch G, Williams ML. Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis. J Invest Dermatol 2001; 117: 837-847.
24. DeLaurenzi V, Rogers G, Hamrock D, Marekov LN, Steinert PM, Compton JG, et al. Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrognease gene. Nat Genet 1996; 12: 52-57.
25. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nature Genetics 2000; 25: 141-142.
26. DiGiovanna JJ. Retinoid treatment of the disorders of cornification. In: Vahlquist A, Duvic M, editors. Retinoids and carotenoids in dermatology. New York: Informa Healthcare Inc., 2007: p. 153-169.
27. Lykkesfeldt G, Hoyer H. Topical cholesterol treatment of recessive x-linked ichthyosis. Lancet 1983; 2: 1337-1338.
28. Chamlin SL, Kao J, Frieden IJ, Sheu MY Fowler, Fluhr JW, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator to disease activity. J Am Acad Dermatol 2002; 47: 198-208.
29. Pope FM, Rees JK, Wells RS, Lewis KGS. Out-patient treatment of ichthyosis: a double-blind trial of ointments. Br J Dermatol 1972; 86: 291-296.
30. van Scott E, Yu R. Control of keratinization with alphahydroxy acids and related compounds. Arch Dermatol 1974; 110: 586-590.
31. Rubeiz N, Kibbi A-G. Management of ichthyosis in infants and children. Clinics Dermatol 2003; 21: 325-328.
32. Buxman M, Hickman J, Ragsdale W, Stretcher G, Krochmal L, Wehr RF. Therapeutic acitivity of lactate 12% lotion in the treatment of ichthyosis. J Am Acad Dermatol 1986; 15: 1253-1258.
33. Küster W, Bohnsack K, Rippke F, Upmeyer H, Groll S, Traupe H. Efficacy of urea therapy in children with ichthyosis. Dermatology 1998; 196: 217-222.
34. Okano M. Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis. Dermatology 2001; 202: 116-118.
35. Gånemo A, Virtanen M, Vahlquist A. Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream mixtures. Br J Dermatol 1999; 141: 1027-1032.
36. Kiistala R, Lauharanta J, Kanerva L. Transepidermal water loss and sweat gland response in lamellar ichthyosis before and during treatment with etretinate: report of three cases. Acta Derm Venereol 1982; 62: 268-269.
37. Ramirez ME, Youseef WF, Romero RG, Martinez JM, Gonzalez-Esenat MA, Vilaplana XS, et al. Acute percutaneous lactic acid poisoning in a child. Ped Dermatol 2006; 23: 282-285.
38. Chiaretti A, Schembri D, Tortorolo L, Piastra M, Polidori G. Salicylate intoxication using a skin ointment. Acta Paediatr 1997; 86: 330-331.
39. Stege H, Hofmann B, Ruzicka T, Lehmann P. Topical application of tazarotene in the treatment of nonerythrodermic lamellar ichthyosis. Arch Dermatol 1998; 134: 640.
40. Redondo P, Bauzá A. Topical N-acetylcysteine for lamellar ichthyosis. The Lancet 1999; 354: 1880.
41. Sarici SU, Sahin M, Yurdakök M. Topical N-acetylcysteine treatment in neonatal ichthyosis. Turk J Pediatr 2003; 45: 245-247.
42. Van de Kerkhof PCM. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol 1995; 132: 675-682.
43. Lucker GPH, van de Kerkhof PCM, van Dijk MR, Steijlen PM. Effect of topical calcipotriol on congenital ichthyosis. Br J Dermatol 1994; 131: 546-550.
44. Borgenrieder T, Landthaler M, Stolz W. Bullous congenital ichthyosiform erythroderma: safe and efficient topical treatment with calciportiol ointment on a child. Acta Derm Venereol 2003; 83: 52-54.
45. Vahlquist A. Ichthyosis - an inborn dryness and scaliness of the skin. In: Lodén M, Maibach HI, editors. Dry skin and moisturizers. New York: CRC Press, Informa, 2006: p. 83-94.
46. Blanchet-Bardon C, Nazzaro V, Rognin C, Geiger, J-M, Puissant A. Acitretin in the treatment of severe disorders of keratinization. J Am Acad Dermatol 1991; 24: 982-986.
47. Steijlen PM, van Dooren-Greebe RJ, van de Kerkhof PC. Acitretin in the treatment of lamellar ichthyosis. Br J Dermatol 1994; 130: 211-214.
48. Peck GL, Gross EG, Butkus D. Comparative analysis of two retinoids in the treatment of disorders of keratinzation. In: Orfanos CE, editor. Retinoids: advances in basic research and therapy. New York: Springer Verlag, 1981: p. 279-286.
49. Sorg O, Kuenzli S, Saurat JH. Side effects and pitfalls in retinoid therapy. In: Vahlquist A, Duvic M, editors. Retinoids and carotenoids in dermatology. New York: Informa Healthcare Inc., 2007: p. 225-248.
50. Virtanen M, Gedde-Dahl T, Mörk N-J, Leigh I, Bowden PE, Vahlquist A. Phenotypic/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression. Acta Derm Venereol 2001; 81: 163-170.
51. Kremer H, Zeeuwen P, McLean WH, Mariman EC, Lane EB, van de Kerkhof CM, et al. Ichthyosis bullosa of Siemens is caused by mutations in the keratin 2e gene. J Invest Dermtol 1994; 103: 286-289.
52. Steijlen PM, Vandoorengreebe RJ, Happle R, Vandekerkhof PCM. Ichthyosis bullosa of Siemens responds well to low-dosage oral retinoids. Br J Dermatol 1991; 125: 469-471.
53. van Wauwe J, Vannyen G, Coene MC, Stoppie P, Cools W, Goossens J, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992; 261: 773-779.
54. Lucker GP, Verfaille CJ, Heremans AM, Vanhoutte FP, Boegeheim JP, Steijlen PM. Topical liarozole in ichthyosis: a double blind, left-right comparative study followed by a long-term open maintenance study. Br J Dermatol, 2005; 152: 566-569.
55. Lucker GP, Heremans AM, Boegheim PJ, van de Kerkhof PC, Steijlen PM. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 1997; 136: 71-75.
56. Van Gysel D, Lijnen RLP, Moekti SS, de Laat PCJ, Oranjet AP. Collodion baby: a follow-up study of 17 cases. J Eur Acad Derm Venereol 2003; 16, 472-475.
57. Lawlor F, Peiris S. Harlequin fetus successfully treated with etretinate. Br J Dermatol 1985; 112: 585-590.
58. Rogers M, Scraf C. Harlequin baby treated with etretinate. Pediatr Dermatol 1989; 6: 216-221.
59. Bojs G, Vrana I, Gånemo A, Vahlquist A. Neonatal acitretin treatment of harlequin ichthyosis. Retinoids 2001; 39: 300-306.
60. Van Gysel D, Koning H, Basert MRM, Savelkoul HFJ, Neijens HJ, Oranje AP. Clinico-Immunological heterogeneity in Comél-Netherton Syndrome. Dermatology 2001; 202: 99-107.
61. Mazereeuw-Hautier J, Cope J, Ong C, Green A, Hovnanian A, Harper JI, Topical recombinant alpha 1-antritrypsin: a potential treatment for Netherton syndrome? Arch Dermatol 2006; 142: 396-398.
62. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, et al. Significant absorption of topical tacrolimus in 3 patients with Netheron syndrome. Arch Dermatol 2001; 137: 747-750.
63. Oji V, Beijan G, Beier K, Traupe H, Luger TA. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005; 153: 1067-1068.
64. Fritsch P. Oral retinoids in Dermatology. Int J Dermatol 1981; 20: 314-329.
65. Willemsen M, Lutt M, Steijlen PM, Cruysberg J, van der Graaf M, Nijhuis-van der Sanden, et al. Clinical and biochemial effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr 2001; 160: 711-717.
66. Jagell S, Lidén S. Treatment of the ichthyosis of the Sjögren-Larsson syndrome with etretinate (Tigason®). Acta Derm Venereol 1983; 3: 89-91.
67. Hickerson RP, Smith FJ, McLean WH, Landthaler M, Leube RE, Kaspar RL. SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann N Y Acad Sci 2006; 1082: 56-61.
68. Khavari PA, Rollman O, Vahlquist A. Cutaneous gene transfer for skin and systemic diseases. J Intern Med 2002; 252: 1-10.
69. Deng H, Choate KA, Lin Q, Khavari PA. High-efficiency gene transfer and pharmacological selection of genetically engineered human keratinocytes. Biotechniques 1998; 25: 274-280.
70. Huang S, Braun-Falco M. Restoration of fatty aldehyde dehydrogenase deficiency in Sjögren-Larsson syndrome. Gene Ther 2006; 13: 1021-1026.